Current treatment regimens for patients with metastatic melanoma are not curative, and new treatment strategies are needed. One possible approach is targeted treatment using the tyrosinase promoter for melanoma-specific expression of genes delivered by adenoviral (Ad) vectors. In this study, a vector with the human minimal tyrosinase promoter and two human enhancer elements (2hE-hTyrP) was compared with different hybrid promoter constructs, containing tyrosinase regulatory sequences and the viral simian virus 40 (SV40) promoter. The tissue specificity of the first-generation vectors was measured by enhanced green fluorescence protein (EGFP) reporter flow cytometry in 12 human melanoma and nonmelanoma cell lines. In the melanotic melanoma cells, the activity of the 2hE-hTyrP promoter was comparable with the activity of the cytomegalovirus promoter, and the background expression levels obtained in the nonmelanoma cell lines confirmed the strict tissue-specific property of this promoter. The hybrid SV40-based promoters were effective, but no tissue specificity was observed even after the inclusion of tyrosinase enhancer elements identical to the elements used in the 2hE-hTyrP promoter. The in vivo tissue specificity of the 2hE-hTyrP vector was demonstrated in subcutaneous xenografted tumors by ex vivo detection of EGFP fluorescence with the IVIS s Imaging equipment and fluorescence microscopy visualizing the in situ EGFP expression in tumor sections. The tyrosinase mRNA level in the 12 cell lines was measured by quantitative real-time RT-PCR, and the expression levels reliably reflected to what extent the 2hE-hTyrP promoter could drive the gene expression in the individual cell lines. In conclusion, the human tyrosinase promoter fused to two human tyrosinase enhancers (2hE-hTyrP) can be used for efficient tissue-specific expression from first-generation Ad vectors in melanoma cell lines both in vitro and in vivo, as predicted by the quantitative tyrosinase mRNA levels in the melanoma and nonmelanoma cell lines tested.
S ystemic treatment of metastatic melanoma has proven difficult and no real improvement has been obtained with any of the new therapeutic modalities that have been investigated. Moreover, the toxicity associated with combined chemo-and biological therapy has prevented further exploration of such treatment approaches. Therefore, strategies that provide specific toxicity to melanoma cells are warranted, and gene therapy in combination with conventional therapeutic modalities may provide an approach for specific targeting of the malignant cells. Recombinant adenoviral (Ad) vectors are widely used as gene vehicles, but the promiscuous nature of adenoviruses may hamper their use in the delivery of potent therapeutic genes. However, selective expression of Ad vector constructs in specific cell types such as melanomas may be obtained by (i) transductional targeting where the binding of the viral fiber is redirected away from the coxsackie adenoreceptor (CAR) to a target cell-specific receptor 1, 2 and (ii) transcriptional targeting using specific promoters to drive selective expression of the transgene in the designated target cell type. [3] [4] [5] [6] Most modalities for transcriptional melanoma targeting utilize the metabolic pathway of melanin synthesis. Tyrosinase is the ratelimiting enzyme in this pathway and its expression is restricted to pigmented cells, including melanoma cells. Upstream of the native human tyrosinase promoter is the enhancer (E), which contains the tyrosinase distal element (TDE) that enhances the tissue-specific transcription of the tyrosinase gene through binding of the microphtalmia-associated transcription factor (MITF). Studies of plasmids containing tyrosinase promoter elements have revealed that at least two enhancers fused to a 260-bp core promoter are required to obtain high and selective expression in melanoma cell lines in vitro. 3, 7, 8 Such promoters have been used for the control of the E1A and E4 genes, creating conditionally replicating adenovirus causing oncolysis of the melanoma cells. 6, [9] [10] [11] [12] However, it has been discussed whether such promoters can be used in first-generation vectors (DE1A, DE3), as Shi et al 5 found that the tyrosinase promoter retains only a small degree of tissue specificity in firstgeneration adenovectors, and that helper-dependent vectors are superior for melanoma-specific expression from the tyrosinase promoter. In this study, we performed quantitative measurements of the tyrosinase mRNA level in a panel of 12 human melanoma and nonmelanoma cell lines, and characterized the efficacy and specificity of the human tyrosinase and hybrid promoters in first-generation adenovectors in these cells. We demonstrate that melanoma specificity could not be obtained when the human tyrosinase enhancer element (E) and/or the tyrosinase distal element (TDE) were combined with the viral simian virus 40 (SV40) promoter. However, when two human tyrosinasespecific enhancers (2hE) were combined with the minimal human promoter sequence (hTyrP), tissue specificity was retained despite the viral elements present in first-generation Ad vectors. Moreover, we show that this promoter (2hE-hTyrP), containing only human tyrosinase promoter elements, was effective for melanomaspecific expression in vivo in subcutaneous (s.c.) tumor xenografts.
Materials and methods

Cell lines and culture conditions
FEMX-I, RMS, SESX, HHMS, THX and LOX have all been established from metastatic lesions of malignant melanoma in patients treated at the Norwegian Radium Hospital. [13] [14] [15] [16] The osteosarcoma cell line, OHS, was established from a bone tumor biopsy. 17 SK-MEL-28 (human melanoma), MeWo (human metastatic melanoma), A549 (human lung carcinoma), SK-BR-3 (human breast adenocarcinoma) and HeLa (human cervix epithelial adenocarcinoma) were obtained from the American Type Culture Collection (Rockville, MD). The 293 (human embryonic kidney) cell line was purchased from Microbix Biosystems Inc. (Toronto, Ontario, Canada). All cells were cultured and maintained in RPMI 1640 medium (Bio Whittaker, Verviers, Belgium), except for 293, which was cultivated in DMEM (Bio Whittaker). The media were supplemented with 10% fetal bovine serum (FBS, PAA Laboratories, Linz, Austria) and 2 mM L-glutamine (GibcoBRL, Paisley, UK). The cells were maintained at 371C in a humidified atmosphere containing 5% CO 2 , and were routinely tested for Mycoplasma infections.
Mouse strain and animal care
Nude mice (NCR nu/nu) were bred in our rodent facility. Female animals 4-6 weeks of age (20-30 g) were used. The animals were housed at constant temperature (23711C) and humidity (5575%). Food and bedding were sterilized and animals were given tap water ad libitum. The animals were euthanized by cervical dislocation. All procedures and experiments involving animals were approved by the National Animal Research Authority and were conducted according to the European Convention for the Protection of Vertebrates Used for Scientific Purposes.
Quantification of tyrosinase gene expression in tumor cell lines by real-time RT-PCR Total RNA isolation was performed using Trizol reagent (Invitrogen, Carlsbad, CA). Reverse transcription was performed on 1 mg RNA using the iScript RT kit from BioRad (BioRad, Hercules, CA). For each PCR, 12.5 ml iQ SYBRGreen Supermix (BioRad), 300 nM of each primer, 5 ml of diluted cDNA and water were added to a final volume of 25 ml. Primer design was accomplished using the software Primer Express from Applied Biosystems (Applied Biosystems, Foster City, CA). The primer set used (forward 5 0 -TCT TCT CCT CTT GGC AGA TTG TC-3 0 , reverse 5 0 -TGT CAT GGT TTC CAG GAT TAC G-3 0 ) amplifies a 114-bp segment spanning exons 1 and 2 of the tyrosinase sequence. Real-time reactions were run on iCycler (BioRad) with the following amplification protocol: 3 minutes initial denaturation at 951C, 50 cycles of 10 seconds denaturation at 951C and 35 seconds annealing/extension at 601C. Detection was obtained by use of SYBRGreen I. The protocol included a melt curve analysis to verify that a single product was amplified. SK-MEL-28 cDNA was serially diluted to generate a standard curve. The standard curve displays a linear relationship between C t (threshold cycle) values and the logarithm of the initial amount of input cDNA. The quality of the RNA samples was verified by amplification of two different genes, the TATA-binding protein (TBP) and the phosphoglycerate kinase 1 (PGK1). The specific products were amplified from all the samples with a small difference in the C t values for each gene. However, due to fluctuations in gene expression ratios (TBP versus PGK1) between the 12 cell lines, these values could not be used for comparison in the quantification of the tyrosinase mRNA levels, and a standard curve based on the amount of total RNA was used for this purpose. The experiments, including isolation of RNA from the cell lines, were performed three times, each time in duplicate (for the standard curve in triplicate). The mean values from each experiment were used to generate a mean for the three experiments.
Construction of promoter cassettes in first-generation Ad vectors
The pShuttle-2hE-hTyrP-EGFP (enhanced green fluorescence protein) was made as described by Siders et al by standard cloning techniques. 3, 18 The human minimal 0 -CCA TGG AAA TGC TCG CTC T-3 0 primer. Two hE elements were cloned into the pShuttle upstream of the minimal tyrosinase promoter. The EGFP was retrieved from Clontech pEGFP.C1 cut with NheI and BamHI, and inserted into the pShuttle multicloning site downstream of the 2hE-hTyrP promoter region.
pGL3-3hTDE-SV40-EGFP was a kind gift from Dr Richard G Vile (Mayo Foundation, Rochester, MN). From this plasmid, the 3hTDE-SV40-EGFP sequence was cloned into pShuttle, and the new plasmid was designated pShuttle-3hTDE-SV40-EGFP. The 2hE fragment was subcloned into pBluescript between the HindIII and XhoI recognition sites in the polylinker, and the pShuttle-2hE-3hTDE-SV40-EGFP was obtained by insertion of the 2hE fragment, from pBluescript-2hE, into the KpnI site directly upstream of the three hTDE elements of pShuttle3hTDE-SV40-EGFP.
The Ad-CMV-EGFP (CMV, cytomegalovirus promoter) was kindly provided by the University of Iowa Gene Transfer Vector Core, Iowa City, IA, USA.
Infectious Ad vectors were generated using the AdEasyt system according to the manufacturer's protocol (Quantum Biotechnologies, Montreal, Canada). The Ad plasmids containing the different promoter structures and EGFP were linearized with PacI and transfected into 293 cells by the use of LIPOFECTIN s reagent (GibcoBRL). Viruses were propagated in 293 cells, purified by cesium chloride gradient ultracentrifugations and titered by plaque assay on 293 cells.
In vitro activity and specificity of the 2hE-hTyrP and the hybrid promoter cassettes in first-generation Ad vectors
To assess the activity of the different promoter cassettes, flow cytometry was used to detect the EGFP expression in live cells infected with the various vectors. Cells (1 Â 10 5 ) were seeded in six-well plates, and 24 hours later, the medium was removed and adenovirus was added in 200 ml phosphate-buffered saline (PBS) supplemented with 0.68 mM CaCl 2 and 0.50 mM MgCl 2 at a multiplicity of infection (MOI) of 50. The cells were incubated with virus while gently rocking for 90 minutes at 371C before fresh medium was added. After 48 hours of incubation, the cells were trypsinized, washed once and resuspended in 500 ml growth medium. Prior to analysis, the samples were filtered through a 50 mm mesh nylon membrane to remove cell aggregates, and stained with propidium iodide (PI; Calbiochem Corp., La Jolla, CA) for viability assessment. EGFP and PI fluorescence measurements were performed using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA). A minimum of 10,000 events were collected for each sample. Data acquisition and analysis were performed with CELLQuest Software (Becton Dickinson). Cell populations other than viable single cells were excluded prior to analysis. All results were adjusted for background fluorescence in untransduced cell populations, and normalized to the expression from the CMV promoter in the respective cell line.
In vivo activity and specificity of the 2hE-hTyrP cassette in first-generation Ad vectors A total of 5 Â 10 6 FEMX-I (melanotic) cells and 1 Â 10 6 , LOX (amelanotic) cells were injected s.c. in nude mice. The tumors were used for experiments when they reached 5-6 mm in diameter to ensure successful tumor development. A total of 5 Â 10 8 plaque forming units (PFU) of Ad-2hE-hTyrP, Ad-CMV and an empty Ad vector were injected intratumorally (i.t.) on two consecutive days, each in three to four animals. Two days after the last injection, the animals were euthanized and the tumor and one lung from each animal were excised and placed individually on black polystyrene plates. Because of high tissue autofluorescence, whole-body in vivo EGFP imaging could not be performed. Instead, EGFP expression in tumors and control lung tissue was measured ex vivo immediately after removal, by the use of a highly sensitive cooled fluorescence CCD camera mounted in a light-tight camera box (IVIS s Imaging System 100 Series with XFO-6 Fluorescence Option, Xenogen Corp., Alameda, CA). Image data acquisition and analysis were performed with Living Image s software (Xenogen Corp.). The animals within the same treatment group were imaged simultaneously, and the imaging time was 10 seconds for all groups. The same fixed size region of interest (ROI) was designated around the tumors and the control tissues (lung) using Living Image s software. Results expressed are total photon counts per ROI. The EGFP expression in all tumors was adjusted for ex vivo background fluorescence in untransduced tissue of the same animal.
To visualize the in situ EGFP expression after i.t. injection of Ad-CMV and Ad-2hE-hTyrP, the tumors were fixed in 4% paraformaldehyde, washed in PBS, embedded in Tissue-Tek s OTC (Sakura Finetek, Torrance, CA) and slowly frozen at À701C, as described elsewhere. 19 Sections (8 mm in thickness) were cut with a cryostat (Jung Frigocut 2800E, Leica, Heidelberg, Germany) and mounted on slides. The sections were analyzed immediately on a research fluorescence microscope (Axioplan 2, Zeiss, Jena, Germany).
Statistical analysis
Relevant statistical tests were performed using SPSS (SPSS, Chicago, IL) software package. Results are expressed as mean7SEM. Correlation was assessed by linear regression. The Mann-Whitney U-test was used to assess the level of significance, and the results were considered statistically significant if Pr.05.
Results
Quantification of tyrosinase mRNA expression in tumor cell lines by real-time RT-PCR
To confirm the classification of the 12 cell lines (melanotic melanomas, amelanotic melanomas and nonmelanomas), the tyrosinase mRNA levels were compared by quantitative real-time RT-PCR using SK-MEL-28 (melanotic melanoma) as a reference. The tyrosinase mRNA expression level per unit RNA in the cell lines is reported as a percentage of the expression in SK-MEL-28 (Table 1) . Among the melanotic melanomas, the expression of tyrosinase mRNA ranged from 100 to 218% of that in SK-MEL-28. The expression of tyrosinase mRNA in amelanotic melanomas and nonmelanomas was almost nondetectable compared to SK-MEL-28 (Table 1) , confirming the classification used throughout the study.
In vitro activity and specificity of 2hE-hTyrP promoter and the hybrid SV40 promoters in first-generation Ad vectors
To measure the activity of the various promoters in the context of first-generation Ad vectors, the cells were infected with the vectors Ad-2hE-hTyrP, Ad-3hTDE-SV40, Ad-2hE-3hTDE-SV40 and Ad-CMV. The schematic structure of each vector is shown in Figure 1 . The activity driven by the human-only tyrosinase promoter (2hE-hTyrP) was remarkably high compared to the CMV promoter in all the melanotic melanoma cell lines: FEMX-I (154%), SK-MEL-28 (99.5%), MeWo (88.3%), RMS (95.5%) and HHMS (99.6%; Fig 2) . The only exception was the SESX cell line, which possessed a more moderate expression with the human tyrosinase promoter (39.6% compared to the CMV promoter). In the amelanotic melanomas and nonmelanomas, the tyrosinase promoter activity was almost undetectable or at very low levels: LOX (0.7%), THX (1.0%), SK-BR-3 (0.3%), HeLa (1.5%), OHS (2.4%) and A549 (5.7%; Fig  2) . The average relative expression level in all the melanomas was 96.1% versus 1.9% in the amelanotic melanomas and nonmelanomas.
When using the tyrosinase-specific distal elements (hTDE) in combination with the strong SV40 promoter in an Ad vector (Ad-3hTDE-SV40), high EGFP expression levels were obtained in all the 12 cell lines. The average expression level from Ad-3hTDE-SV40 in melanotic melanomas was 160% compared to 141% in amelanotic melanomas and nonmelanomas (Fig 3) , indicating that tissue specificity could not be achieved in the context of first-generation adenovirus with this combination of hybrid promoter elements. With the possibility that upstream viral sequences interfered with the TDE elements, and with the superior tissue specificity of the Ad-2hE-hTyrP construct in mind, two tyrosinase enhancer elements (2hE, 400 bp) were included upstream of the 3hTDE elements, resulting in the pShuttle-2hE-3hTDE-SV40 construct. When this plasmid was transfected into melanoma and nonmelanoma cell lines, tissue-specific expression was obtained (data not shown). However, when this promoter construct was included in a first-generation Ad vector (Ad-2hE-3hTDE-SV40), the two human enhancer elements were not able to retain their tissue-specific property (average expression in melanotic melanomas 127%, in amelanotic melanomas and nonmelanomas 111%). Our results clearly demonstrate the efficacy of the hybrid promoters, but the 2hE-hTyrP was the only promoter construct conferring strictly melanoma-specific expression. Figure 1 Schematic structures of the human tyrosinase promoter and the SV40 hybrid promoters. The E1-and E3-deleted replicationincompetent Ad vectors include the minimal hTyr promoter (nucleotides À209 to þ 51) fused to two copies of the hE (enhancer; nucleotides À2014 to À1820) in Ad-2hE-hTyrP, the SV40 promoter (195 bp) combined with two hE and three hTDE (tyrosinase distal element) in Ad-2hE-3hTDE-SV40 and three hTDE only in Ad-3hTDE-SV40. All promoters control the expression of the EGFP reporter.
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Correlation between the tyrosinase mRNA expression level and the 2hE-hTyrP promoter activity in melanoma and nonmelanoma cell lines
The expression of the tyrosinase mRNA in each cell line is among other factors dependent on the activity of the native tyrosinase promoter. We therefore wanted to assess whether the tyrosinase mRNA expression level could predict the activity of the artificial 2hE-hTyrP promoter in a first-generation Ad vector in the various cell lines. As expected, the expression levels of tyrosinase mRNA (measured by quantitative real-time RT-PCR) and the expression from the 2hE-hTyrP promoter (measured by EGFP flow cytometry) correlated with a significant positive slope (beta ¼ 0.553, P ¼ .001; Fig 4) , indicating a significant relationship between the tyrosinase mRNA levels and expression from this artificial human tyrosinase promoter. 
In vivo activity and specificity of the 2hE-hTyrP promoter in first-generation Ad vectors
To analyze the activity of the 2hE-hTyrP-promoter in vivo, the recombinant adenoviruses Ad-2hE-hTyrP and Ad-CMV were administered i.t. on two consecutive days into s.c. FEMX-I (melanotic) and LOX (amelanotic) tumors in nude mice. Two days after the last injection, EGFP expression in the tumors was quantified ex vivo by use of IVIS s Imaging System. The expression driven by the 2hE-hTyrP promoter is presented as a percentage of expression driven by the CMV promoter. Figure 5 illustrates that the 2hE-hTyrP activity is higher than the CMV activity in the melanotic melanoma FEMX-I tumors (139%), but the difference in expression efficacy was not significant (P ¼ .77). In the amelanotic LOX tumors, the expression with the human tyrosinase promoter was at background levels (24%) defined by injection of an empty Ad vector. The 2hE-hTyrP promoter activity was significantly lower than the CMV promoter activity in the amelanotic tumors (P ¼ .03). Similar results were obtained when tumor cells were infected with the viral vectors in vitro, injected s.c. and measured for the expression of EGFP after tumor formation, as described in Materials and methods. These results confirm that the EGFP expression driven by the 2hE-hTyrP promoter in a first-generation Ad vector was very low in the nontarget amelanotic LOX tumors, and that the same promoter was at least as effective as the CMV promoter in the tyrosinase-positive FEMX-I melanoma tumors.
To confirm the results obtained with the IVIS s Imaging System, tumor sections were analyzed by fluorescence microscopy. In sections of the FEMX-I tumors, EGFP fluorescence was found in tumors injected with Ad-CMV or Ad-2hE-hTyrP, whereas background expression was demonstrated in the Ad vector-treated tumors (Fig 6) . However, in the mice bearing LOX tumors, strong EGFP expression could only be detected in the tumors treated with Ad-CMV, as both Ad vector and Ad-2hE-hTyrP resulted in background expression.
Discussion
Biological molecules such as interferon-a (IFN-a) , interleukin-2 (IL-2) and tumor necrosis factor-a (TNF-a) have been extensively investigated for their potential role as adjuncts in the treatment of patients with malignant melanoma. These molecules are biologically potent, but systemic toxicity has limited the use of these molecules in therapy. However, targeted delivery of such molecules by Ad gene therapy vectors may provide a rational approach for the treatment of disseminated melanoma disease.
Strong and melanoma-specific gene expression have been demonstrated in plasmid constructs containing a tandem of the tyrosinase enhancer elements fused to the tyrosinase core promoter. However, in 2002, Shi et al found that the tyrosinase promoter retained only a small degree of tissue specificity when incorporated into Figure 4 Regression analysis of the correlation between the expression efficiency of the 2hE-hTyrP promoter versus the tyrosinase mRNA level in melanoma and nonmelanoma cell lines. The amount of tyrosinase mRNA in 12 cell lines was determined by quantitative RT-PCR. Regression analysis was used to determine whether the tyrosinase mRNA expression could be used to predict the EGFP expression level when driven by the tyrosinase (2hE-hTyrP) promoter. 2hE-hTyP promoter activity is shown relative to the activity of CMV promoter-driven EGFP expression in the same cell line. The tyrosinase mRNA level is expressed relative to the corresponding expression in SK-MEL-28. The mean of three individual experiments performed in duplicate is shown. first-generation Ad vectors, and that helper-dependent Ad vectors were superior for melanoma-specific expression from this promoter. Shi et al's reported promoter constructs included the human tyrosinase core promoter in combination with two murine enhancers (2mE-hTyrP), whereas, in this study, we combined the human minimal tyrosinase promoter with two human tyrosinase enhancer elements (2hE-hTyrP). By the use of only human promoter elements, we obtained an average relative expression level of 96.1% in melanotic cells compared to 1.9% in amelanotic melanomas and nonmelanomas, confirming the strictly selective expression profile of this promoter in vitro. The 2hE-hTyrP promoter also proved to be strong, as the activity in five of the six melanotic melanoma cell lines was comparable with the CMV activity. The only exception was in the tyrosinase-positive SESX line (39.6% of the CMV promoter). The reason for this discrepancy is not known.
Strict melanoma-specific expression has been obtained in other vector systems using hybrid promoter combinations. A retroviral vector containing three tyrosinase distal elements (3hTDE) fused to the strong viral SV40 promoter was found to drive both efficient and selective expression in melanoma cells. 20 However, when we incorporated this hybrid promoter into a first-generation Ad vector (Ad-3hTDE-SV40), strong expression was observed in all cell lines, and hence melanoma specificity was not obtained. We wanted, therefore, to investigate if the loss of tissue specificity was due to influences by sequences in the Ad backbone and the lack of separation between the viral internal terminal repeat region and the TDE sequences. Given the superior specificity of the Ad-2hE-hTyrP construct, two identical human enhancer elements (2hE) were cloned upstream of the three TDE in the 2hE-3TDE-SV40 plasmid. Transient transfections with this plasmid in melanoma and nonmelanoma cell lines conferred melanotic melanoma-specific reporter expression. Nevertheless, when the tyrosinase promoter elements were combined with the strong viral SV40 promoter in a first-generation Ad vector (Ad-2hE-3TDE-SV40), the melanoma-specific properties of the tyrosinase promoter elements were abolished. As proposed by other investigators, the results indicate that the Ad sequences or proteins through an interaction with strong viral promoters (in this case, the SV40 promoter) may over-ride the tyrosinase-specific enhancers. 5 It is also probable, as Shi et al suggested, that expression from tissue-or tumor-specific promoters may be influenced by Ad sequences upstream of the E1A promoter region, but in our study the 2hE-hTyrP promoter retained a good tissue-specific expression in the melanoma and nonmelanoma cell lines tested. Consequently, not only helper-dependent, but also firstgeneration Ad vectors based on the human tyrosinase promoter may be useful in melanoma-specific delivery of therapeutic genes. Moreover, the 2hE-hTyrP promoter proved to be selective and to drive efficient expression in FEMX-I melanoma cells, originally derived from a metastatic lymph node in a patient, injected s.c. in nude mice. As for the in vitro studies, the expression of the reporter gene with 2hE-hTyrP was comparable with the expression with the CMV promoter in the FEMX-I tumors, whereas the expression with this promoter in amelanotic LOX tumors remained at the background level. The in situ specificity of the Ad-2hE-hTyrP vector was also confirmed by fluorescence microscopy of sections of the tyrosinasepositive FEMX-I and tyrosinase-negative LOX tumors. Thus, the 2hE-hTyrP promoter is a good candidate promoter for targeted delivery of therapeutic genes, also from first-generation Ad vectors, to melanoma cells in vivo. In addition, these results acknowledge the relevance of using such promoters in conditionally replicating Ad vectors, as recently described. 11, 12 The strong and ubiquitously expressing CMV promoter has been extensively used in gene therapy vectors. The transient expression obtained with first-generation Ad vectors is well known, and lately it was found that the major mechanism behind the decreased expression observed was transcriptional silencing due to methylation of the CMV promoter. 21 Silencing is most likely a consequence of the origin of the sequences in the promoter, and even though the over time fate of the 2hE-hTyrP promoter has not been investigated, we hypothesize that silencing of this construct is less likely to occur, as it contains only human sequences (for review see Papadakis et al 22 ) . The tyrosinase mRNA level in 12 cell lines was measured by quantitative real-time RT-PCR and the result was used as the independent variable in a linear regression model for prediction of the 2hE-hTyrP promoter activity. We found a significant positive correlation between the tyrosinase mRNA expression levels and the activity of the 2hE-hTyrP promoter in the cell lines tested. Tyrosinase mRNA does not regulate its own promoter, and measurements of a transcription factor, which does affect the promoter directly, may be a better predictor for the 2hE-hTyrP activity. The human tyrosinase enhancers (E) and TDE included in the promoters tested in this study contain the consensus binding sequence of the transcription factor MITF. Efforts have been made to clarify the effect of MITF on the native tyrosinase promoter, and recently it was shown that MITF is required, but is not sufficient to induce the expression of tyrosinase. 23 The tyrosinase enzyme expression seems to be controlled by multiple activators and repressors, and it is uncertain if the expression level of the MITF factor in the cell lines could be used to predict the activity of the artificial human tyrosinase promoter (2hE-hTyrP). We therefore decided to study if the level of tyrosinase mRNA, a direct product of the native tyrosinase promoter, could predict the expression of a gene from the artificial 2hE-hTyrP promoter. Despite the fact that the mRNA level in a cell line may be influenced by post-transcriptional processing (splicing, degradation etc.), we were able to predict the 2hE-hTyrP promoter activity, by measuring the tyrosinase mRNA level in the respective cell lines.
The Ad-2hE-hTyrP vector proved to drive efficient and specific transgene expression both in vitro and in vivo. However, treatment of metastatic disease requires systemic administration, and the potential for Ad vectors may therefore be impeded by their promiscuity and sequestration by the liver, leaving too few particles available for the target tissue. Studies have demonstrated higher transduction ratios of melanoma cells when the uptake of the viral vector has been retargeted to a v integrins and HMWMAA (high-molecular-weight melanoma-associated antigen), 1, 24 and sophisticated specificity has been obtained by combining transcriptional targeting and transductional targeting. 11, 12 A dual targeting strategy will be of value for delivery of toxic genes with the 2hE-hTyrP-based vector, to enhance both the efficacy and the specificity for metastatic melanoma cells.
In conclusion, this study shows that the combination of the human tyrosinase core promoter with two human tyrosinase enhancer elements (2hE-hTyrP) mediated efficient and tight melanoma-specific expression of the EGFP reporter gene, both in vitro and in vivo, when delivered by a first-generation Ad vector. However, the melanoma-specific property of the tyrosinase promoter elements was abolished when these elements were combined with the strong viral SV40 promoter. Furthermore, quantitative measurements of the tyrosinase mRNA level in melanoma and nonmelanoma cell lines was used to predict if the artificial 2hE-hTyrP promoter could drive EGFP transgene expression in the various cell lines.
Due to the strict selectivity of the 2hE-hTyrP promoter, first-generation Ad vectors may be a reliable tool for targeted delivery of therapeutic genes to melanoma cells. In combination with traditional chemotherapy, such targeted vectors might represent an efficient strategy for gene therapy of disseminated malignant melanoma.
